免费获得国外相关药品，最快 1 个工作日回馈药物信息
出境医 / 临床实验 / The Role of Midkine in Diagnosis of Thyroid Cancer
The Role of Midkine in Diagnosis of Thyroid Cancer
Study Description
Brief Summary:
- Evaluation of the role of serum midkine in differentiating malignant from benign thyroid nodule
- studying the level of serum midkine in relation to different thyroid cancer stages
| Condition or disease |
|---|
| Thyroid Cancer |
Study Design
| Study Type : | Observational |
| Estimated Enrollment : | 85 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Retrospective |
| Official Title: | The Role of Midkine in Diagnosis of Thyroid Cancer |
| Estimated Study Start Date : | September 2019 |
| Estimated Primary Completion Date : | November 2020 |
| Estimated Study Completion Date : | December 2020 |
Arms and Interventions
Outcome Measures
Primary Outcome Measures :
- serum midkine levels [ Time Frame: Baseline ]
Eligibility Criteria
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
This study will be conducted on 85 informed and consented individuals (according to the guidelines of ethical committee of faculty of Medicine, Assuit University ) The study will include 30 patients with thyroid cancer and 30 patients with benign thyroid diseases. The study will also include 25 aged matched apparently healthy individuals as a control group.
Criteria
Inclusion Criteria:
patient with thyroid nodule
Exclusion Criteria:
- Other known organ tumour
- Chemothyrapy
- Radiothyrapy c. Sample Size Calculation
Contacts and Locations
Contacts
| Contact: Marwa Hassan, Master | 01004748373 | meromoro1010@gmail.com |
Sponsors and Collaborators
Assiut University
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | November 24, 2018 | ||||
| First Posted Date | June 7, 2019 | ||||
| Last Update Posted Date | June 7, 2019 | ||||
| Estimated Study Start Date | September 2019 | ||||
| Estimated Primary Completion Date | November 2020 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures |
serum midkine levels [ Time Frame: Baseline ] | ||||
| Original Primary Outcome Measures | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures | Not Provided | ||||
| Original Secondary Outcome Measures | Not Provided | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title | The Role of Midkine in Diagnosis of Thyroid Cancer | ||||
| Official Title | The Role of Midkine in Diagnosis of Thyroid Cancer | ||||
| Brief Summary |
|
||||
| Detailed Description | Not Provided | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Case-Control Time Perspective: Retrospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | This study will be conducted on 85 informed and consented individuals (according to the guidelines of ethical committee of faculty of Medicine, Assuit University ) The study will include 30 patients with thyroid cancer and 30 patients with benign thyroid diseases. The study will also include 25 aged matched apparently healthy individuals as a control group. | ||||
| Condition | Thyroid Cancer | ||||
| Intervention | Not Provided | ||||
| Study Groups/Cohorts | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status | Unknown status | ||||
| Estimated Enrollment |
85 | ||||
| Original Estimated Enrollment | Same as current | ||||
| Estimated Study Completion Date | December 2020 | ||||
| Estimated Primary Completion Date | November 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria |
Inclusion Criteria: patient with thyroid nodule Exclusion Criteria:
|
||||
| Sex/Gender |
|
||||
| Ages | Child, Adult, Older Adult | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Not Provided | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03978351 | ||||
| Other Study ID Numbers | Marwa Hassan | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement | Not Provided | ||||
| Responsible Party | Marwa Hassan Thabet Ahmed, Assiut University | ||||
| Study Sponsor | Assiut University | ||||
| Collaborators | Not Provided | ||||
| Investigators | Not Provided | ||||
| PRS Account | Assiut University | ||||
| Verification Date | September 2018 | ||||
